J.E.M. Tech is thrilled to announce a successful funding round, having raised €120,000 to further advance its revolutionary medical technology. This significant investment underscores the confidence that investors have in J.E.M. Tech’s pioneering approach to cardiac care. The company has developed and implemented the first Videocardiografo (VCG), a cutting-edge, non-invasive medical device that leverages artificial intelligence to assess the mechanical function of the heart in real time using only a standard camera. By enabling cardiac surgeons to review a patient’s heart performance at critical moments during surgery, the VCG is poised to transform intraoperative decision-making and ultimately improve patient outcomes.
The infusion of new capital will allow J.E.M. Tech to accelerate the widespread deployment of the VCG, enhance its technological capabilities, and further validate its clinical efficacy through robust research and testing. With a clear focus on personalized, non-invasive medical solutions, the company’s vision is to provide a diagnostic and prognostic tool that not only reduces the mortality rate in cardiac patients but also streamlines post-surgical recovery by minimizing time in intensive care. The mission remains firmly on developing an all-in-one device that supports diagnosis, intraoperative evaluation, and prognosis for patients with heart conditions, simplifying the complex process of clinical data interpretation and empowering medical professionals with a reliable decision support system.
This remarkable funding milestone marks a new chapter for J.E.M. Tech and serves as a testament to its commitment to revolutionizing cardiac care through innovation and excellence. The company looks forward to leveraging these funds to enhance patient outcomes while continuing to push the boundaries of medical technology.
